University of Tasmania
Browse

Lumiracoxib (Novartis)

Download (95.76 kB)
journal contribution
posted on 2023-05-26, 15:41 authored by Ding, C, Jones, G
Lumiracoxib, an inhibitor of cyclooxygenase 2 (COX-2), is under development by Novartis for the potential treatment of osteoarthritis, rheumatoid arthritis and pain. By late December 2000, phase III trials had been initiated and were ongoing in December 2001.

History

Publication title

IDrugs

Volume

5

Article number

12

Number

12

Pagination

1168-1172

ISSN

1369-7056

Publication status

  • Published

Repository Status

  • Open

Usage metrics

    University Of Tasmania

    Categories

    No categories selected

    Keywords

    No keyword provided

    Licence

    In Copyright

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC